hydrocodone (PTI-721) / Cassava - LARVOL DELTA

Pain Therapeutics reports Pfizer elects to continue development of Remoxy (Pain Therapeutics Press Release) - "Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported Pfizer Inc. (NYSE:PFE) has informed us that, having achieved technical milestones related to manufacturing, they will continue the development program for REMOXY® (oxycodone) Extended-Release Capsules CII....The complete response submission is not expected to occur prior to mid-2015....Pfizer has returned to us all rights with respect to abuse-resistant formulations of hydrocodone, hydromorphone and oxymorphone....We are now free to develop and commercialize these assets on our own or with a licensee of our choice, and may do so without notice or approval from Pfizer."

Anticipated FDA event • Pipeline update • Pain